Chagas Disease - Pipeline Review, H1 2017
Chagas Disease - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.
Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 4 molecules, respectively.
Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.
Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 4 molecules, respectively.
Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Chagas Disease (American Trypanosomiasis) - Overview
Chagas Disease (American Trypanosomiasis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Company Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals Inc
Kancera AB
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Chagas Disease (American Trypanosomiasis) - Drug Profiles
benznidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benznidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLBS-1246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLBS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNF-6702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0441411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAO-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEU-321 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas Disease (American Trypanosomiasis) - Dormant Projects
Chagas Disease (American Trypanosomiasis) - Discontinued Products
Chagas Disease (American Trypanosomiasis) - Product Development Milestones
Featured News & Press Releases
Apr 06, 2017: Benznidazole on Track in Progress to IND and NDA Submissions
Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole
Dec 12, 2016: KaloBios Completes Meeting with FDA for Benznidazole
Nov 15, 2016: Bayer to Fight Chagas Disease in Children
Aug 08, 2016: A single compound could treat three parasitic diseases
Apr 11, 2016: KaloBios Announces New Product Pricing Model
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Chagas Disease (American Trypanosomiasis) - Overview
Chagas Disease (American Trypanosomiasis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Company Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals Inc
Kancera AB
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Chagas Disease (American Trypanosomiasis) - Drug Profiles
benznidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benznidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLBS-1246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLBS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNF-6702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0441411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAO-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEU-321 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas Disease (American Trypanosomiasis) - Dormant Projects
Chagas Disease (American Trypanosomiasis) - Discontinued Products
Chagas Disease (American Trypanosomiasis) - Product Development Milestones
Featured News & Press Releases
Apr 06, 2017: Benznidazole on Track in Progress to IND and NDA Submissions
Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole
Dec 12, 2016: KaloBios Completes Meeting with FDA for Benznidazole
Nov 15, 2016: Bayer to Fight Chagas Disease in Children
Aug 08, 2016: A single compound could treat three parasitic diseases
Apr 11, 2016: KaloBios Announces New Product Pricing Model
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Kancera AB, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2017
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2017
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2017
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Kancera AB, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H1 2017
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2017
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2017
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2017
LIST OF FIGURES
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Company Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals Inc
Kancera AB
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Company Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals Inc
Kancera AB
Novartis AG
Oblita Therapeutics BVBA
Sanofi
